Related Experiment Videos
[Neuronal ceroid lipofuscinoses].
Liv Berit Augestad1, Jørgen Diderichsen
1Fakultet for samfunnsvitenskap og, teknologiledelse, Norges teknisk-naturvitenskapelige universitet, 7491 Trondheim. livba@svt.ntnu.no.
Summary
Neuronal ceroid lipofuscinoses (NCL) are rare, inherited neurological diseases causing vision loss and developmental failure. Current research focuses on genetic diagnostics and developing treatments like gene therapy for NCL.
Area of Science:
- Neurology
- Genetics
- Cell Biology
Context:
- Neuronal ceroid lipofuscinoses (NCL) encompass a group of rare, inherited neurodegenerative disorders.
- These conditions are characterized by the accumulation of autofluorescent ceroid and lipofuscin in neuronal and extraneuronal cells.
- NCL presents with diverse clinical manifestations, including visual impairment, psychomotor developmental delay, seizures, and premature mortality.
Purpose:
- To review and synthesize current research on the diagnostics and therapeutic strategies for NCL.
- To provide an overview of the genetic basis and clinical classifications of NCL.
- To highlight the advancements in understanding and managing these complex neurological diseases.
Summary:
- NCL comprises infantile, late infantile, juvenile, and adult-onset forms, with genetic defects identified in at least six genes.
- Diagnosis historically relied on clinical evaluation, ophthalmologic and neurophysiological testing, and examination of vacuolated lymphocytes, now complemented by genetic testing.
- While no cure exists, ongoing research explores enzyme replacement, gene therapy, stem cell transplantation, and pharmacotherapy, alongside essential symptomatic and palliative care.
Impact:
- Advances in genetic testing have refined NCL diagnosis and classification.
- Research into novel therapeutic approaches offers hope for improved management and potential treatments for NCL patients.
- This review consolidates knowledge, guiding future research and clinical practice in NCL.